Biological Activity Cagrilintide and semaglutide, when co-administered, produce synergistic reductions in bodyweight (up to ~1517% over 2032 weeks in clinical trials) and significant improvements in glycemic parameters, including HbA1c and fasting glucose
or ii) aged 60 years with at least one CV risk factor (persistent microalbuminuria or proteinuria, hypertension with left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, or an anklebrachial index 7% in PIONEER 6 and different restrictions on permitted background glucose-lowering medication
We tailor your appeal to address your insurance's prior authorization requirements and reason for denial
(PubMed) Rahimdel A, Zeinali A, Yazdian-Anari P, Hajizadeh R, Arefnia E
Preventative measures The following measures are essential to reduce the chance of flares and organ damage